Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series

Preeti Raghavan, Ying Lu, Mona Mirchandani, Antonio Stecco

Research output: Contribution to journalArticle

Abstract

Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However, current treatment options for spasticity produce muscle weakness which can impede movement, and do not directly address muscle stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes the development of muscle stiffness, and report that treatment with the enzyme hyaluronidase increases upper limb movement and reduces muscle stiffness without producing weakness. 20 patients with unilateral upper limb spasticity received multiple intramuscular injections of human recombinant hyaluronidase with saline at a single visit. The safety and efficacy of the injections, passive and active movement, and muscle stiffness at eight upper limb joints were assessed at four time points: pre-injection (T0), within 2 weeks (T1), within 4–6 weeks (T2), and within 3–5 months post-injection (T3). There were no clinically significant adverse effects from the injections. Passive movement at all joints, and active movement at most joints increased at T1, and persisted at T2 and T3 for most joints. The modified Ashworth scores also declined significantly over time post-injection. Hyaluronidase injections offer a safe and potentially efficacious treatment for muscle stiffness in neurologically impaired individuals. These results warrant confirmation in placebo-controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalEBioMedicine
Volume9
DOIs
StatePublished - 2016

Fingerprint

Hyaluronoglucosaminidase
Upper Extremity
Muscle
Stiffness
Muscles
Injections
Wounds and Injuries
Joints
Nervous System Trauma
Muscle Spasticity
Muscle Development
Intramuscular Injections
Muscle Weakness
Controlled Clinical Trials
Contracture
Hyaluronic Acid
Neurology
Therapeutics
Central Nervous System
Placebos

Keywords

  • Case series
  • Connective tissue
  • Fascia
  • Hyaluronidase
  • Hypertonia
  • Motor control
  • Spasticity
  • Stroke

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury : A Case Series. / Raghavan, Preeti; Lu, Ying; Mirchandani, Mona; Stecco, Antonio.

In: EBioMedicine, Vol. 9, 2016, p. 306-313.

Research output: Contribution to journalArticle

@article{1057658d94e74633a6a0bb0b3c74835a,
title = "Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series",
abstract = "Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However, current treatment options for spasticity produce muscle weakness which can impede movement, and do not directly address muscle stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes the development of muscle stiffness, and report that treatment with the enzyme hyaluronidase increases upper limb movement and reduces muscle stiffness without producing weakness. 20 patients with unilateral upper limb spasticity received multiple intramuscular injections of human recombinant hyaluronidase with saline at a single visit. The safety and efficacy of the injections, passive and active movement, and muscle stiffness at eight upper limb joints were assessed at four time points: pre-injection (T0), within 2 weeks (T1), within 4–6 weeks (T2), and within 3–5 months post-injection (T3). There were no clinically significant adverse effects from the injections. Passive movement at all joints, and active movement at most joints increased at T1, and persisted at T2 and T3 for most joints. The modified Ashworth scores also declined significantly over time post-injection. Hyaluronidase injections offer a safe and potentially efficacious treatment for muscle stiffness in neurologically impaired individuals. These results warrant confirmation in placebo-controlled clinical trials.",
keywords = "Case series, Connective tissue, Fascia, Hyaluronidase, Hypertonia, Motor control, Spasticity, Stroke",
author = "Preeti Raghavan and Ying Lu and Mona Mirchandani and Antonio Stecco",
year = "2016",
doi = "10.1016/j.ebiom.2016.05.014",
language = "English (US)",
volume = "9",
pages = "306--313",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury

T2 - A Case Series

AU - Raghavan, Preeti

AU - Lu, Ying

AU - Mirchandani, Mona

AU - Stecco, Antonio

PY - 2016

Y1 - 2016

N2 - Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However, current treatment options for spasticity produce muscle weakness which can impede movement, and do not directly address muscle stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes the development of muscle stiffness, and report that treatment with the enzyme hyaluronidase increases upper limb movement and reduces muscle stiffness without producing weakness. 20 patients with unilateral upper limb spasticity received multiple intramuscular injections of human recombinant hyaluronidase with saline at a single visit. The safety and efficacy of the injections, passive and active movement, and muscle stiffness at eight upper limb joints were assessed at four time points: pre-injection (T0), within 2 weeks (T1), within 4–6 weeks (T2), and within 3–5 months post-injection (T3). There were no clinically significant adverse effects from the injections. Passive movement at all joints, and active movement at most joints increased at T1, and persisted at T2 and T3 for most joints. The modified Ashworth scores also declined significantly over time post-injection. Hyaluronidase injections offer a safe and potentially efficacious treatment for muscle stiffness in neurologically impaired individuals. These results warrant confirmation in placebo-controlled clinical trials.

AB - Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However, current treatment options for spasticity produce muscle weakness which can impede movement, and do not directly address muscle stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes the development of muscle stiffness, and report that treatment with the enzyme hyaluronidase increases upper limb movement and reduces muscle stiffness without producing weakness. 20 patients with unilateral upper limb spasticity received multiple intramuscular injections of human recombinant hyaluronidase with saline at a single visit. The safety and efficacy of the injections, passive and active movement, and muscle stiffness at eight upper limb joints were assessed at four time points: pre-injection (T0), within 2 weeks (T1), within 4–6 weeks (T2), and within 3–5 months post-injection (T3). There were no clinically significant adverse effects from the injections. Passive movement at all joints, and active movement at most joints increased at T1, and persisted at T2 and T3 for most joints. The modified Ashworth scores also declined significantly over time post-injection. Hyaluronidase injections offer a safe and potentially efficacious treatment for muscle stiffness in neurologically impaired individuals. These results warrant confirmation in placebo-controlled clinical trials.

KW - Case series

KW - Connective tissue

KW - Fascia

KW - Hyaluronidase

KW - Hypertonia

KW - Motor control

KW - Spasticity

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84971635782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971635782&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2016.05.014

DO - 10.1016/j.ebiom.2016.05.014

M3 - Article

C2 - 27333050

AN - SCOPUS:84971635782

VL - 9

SP - 306

EP - 313

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -